Clinicians >
mCRC Clinical Studies


mCRC Clinical Studies

Three large RCTs are investigating the first-line use of SIR-Spheres® Y-90 resin microspheres in metastatic colorectal cancer (mCRC). Key endpoints from the SIRFLOX study were reported at the ASCO 2015 Annual Meeting and published in the Journal of Clinical Oncology in 2016.  Overall Survival, the primary endpoint of the FOXFIRE and FOXFIRE Global studies which share a very similar study design to SIRFLOX, is expected in 2017. These data will be combined with the overall survival result from SIRFLOX, representing >1100 subjects, in a pre-planned combined analysis.

In addition to the SIRFLOX and FOXFIRE studies, other clinical studies are currently investigating the treatment of mCRC, HCC, and other unresectable liver tumours with SIR-Spheres Y-90 resin microspheres.

SIR-Spheres Y-90 resin microspheres have been extensively used in the treatment of liver metastases from colorectal cancer. Numerous studies, including randomised controlled trials, have been published on the combination of SIR-Spheres Y-90 resin microspheres with first-line chemotherapy, as well as in subsequent lines in combination with chemotherapy or as a single agent for mCRC. View summary of published data for SIR-Spheres Y-90 resin microspheres in the treatment of mCRC



Publication selected in
„Best of JCO“

New mCRC data
coming in 2017

New mCRC data
coming in 2017


Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×

This content is intended for healthcare professionals only

By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage